Skip to main content

Combination of Immunotherapy and Radiation Therapy for Non-small Cell Lung Cancer: Efficacy and Toxicity, Validated Biomarkers, and Mechanistic Studies

35kviews
Background: The current review aimed to pool real-world evidence on the efficacy and toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer (NSCLC) after curative chemoradiotherapy. Methods: PubMed, CENTRAL, ScienceDirect, Embase, and Google Scholar were searched for observational studies reporting the use of durvalumab for NSCLC till 12th April 2022. Twenty-three studies with 4400 patients were included. Results: The pooled 1-year overall survival (OS) and progression-free survival rates (PFS) were 85% (95% CI: 81-89%) and 60% (95% CI: 56-64%) respectively. Pooled incidence of all-grade pneumonitis, grade ≥3 pneumonitis and discontinuation of durvalumab due to pneumonitis were 27% (95% CI: 19-36%), 8% (95% CI: 6-10%) and 17% (95% CI: 12-23%) respectively. The pooled proportion of patients experiencing endocrine, cutaneous, musculoskeletal, and gastrointestinal adverse events was 11% (95% CI: 7-18%), 8% (95% CI: 3-17%), 5% (95% CI: 3-6%), and 6% (95% CI: 3-12%) respectively. Conclusion: Meta-regression indicated that performance status significantly influenced PFS, while age, time to durvalumab, and programmed death-ligand 1 status significantly affected pneumonitis rates. Real-world evidence suggests that the short-term efficacy and safety of durvalumab are consistent with that of the PACIFIC trial. The congruence of results lends support to durvalumab use in improving outcomes of unresectable stage III NSCLC.

5,784 views

28 citations

MINI REVIEW
8 February 2023
Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
Xiaofei Zhang, 6 more and Weixin Zhao

4,677 views

8 citations

SYSTEMATIC REVIEW
28 November 2022
RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis
Min Wu, 4 more and Rong Chen

2,967 views

4 citations

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
ORIGINAL RESEARCH
6 October 2022
Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
Dong Xie, 8 more and Hongjie Hu

5,119 views

34 citations